{"title":"Increased levels of nectin-4 as a serological marker for pre-eclampsia.","authors":"Hikari Yoshizawa, Haruki Nishizawa, Mayuko Ito, Akiko Ohwaki, Yoshiko Sakabe, Takao Sekiya, Takuma Fujii, Hiroki Kurahashi","doi":"10.20407/fmj.2022-027","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Nectin-4 is a cell adhesion molecule with vital functions at adherens and tight junctions. Cumulative evidence now indicates that the <i>NECTIN4</i> gene is overexpressed in a variety of cancers, and that the nectin-4 protein is both a disease marker and therapeutic target in a subset of these cancers. We previously demonstrated that <i>NECTIN4</i> is overexpressed in placenta during pre-eclamptic pregnancy, which is one of the most serious obstetric disorders.</p><p><strong>Methods: </strong>Nectin-4 protein levels were measured in maternal sera from pregnant women with pre-eclampsia and its related disorder, unexplained fetal growth retardation.</p><p><strong>Results: </strong>Maternal serum concentrations of nectin-4 were significantly elevated in pre-eclamptic women compared with those with an uncomplicated normotensive pregnancy. However, no increase was observed in pregnancies with unexplained fetal growth retardation. Serum nectin-4 levels were higher in cases with early-onset pre-eclampsia that generally showed more severe clinical symptoms, but levels were not correlated to other clinical indicators of disease severity.</p><p><strong>Conclusions: </strong>Nectin-4 is a potential new diagnostic and predictive biomarker for severe pre-eclampsia.</p>","PeriodicalId":33657,"journal":{"name":"Fujita Medical Journal","volume":"9 3","pages":"200-205"},"PeriodicalIF":0.0000,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10405896/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Fujita Medical Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.20407/fmj.2022-027","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Objectives: Nectin-4 is a cell adhesion molecule with vital functions at adherens and tight junctions. Cumulative evidence now indicates that the NECTIN4 gene is overexpressed in a variety of cancers, and that the nectin-4 protein is both a disease marker and therapeutic target in a subset of these cancers. We previously demonstrated that NECTIN4 is overexpressed in placenta during pre-eclamptic pregnancy, which is one of the most serious obstetric disorders.
Methods: Nectin-4 protein levels were measured in maternal sera from pregnant women with pre-eclampsia and its related disorder, unexplained fetal growth retardation.
Results: Maternal serum concentrations of nectin-4 were significantly elevated in pre-eclamptic women compared with those with an uncomplicated normotensive pregnancy. However, no increase was observed in pregnancies with unexplained fetal growth retardation. Serum nectin-4 levels were higher in cases with early-onset pre-eclampsia that generally showed more severe clinical symptoms, but levels were not correlated to other clinical indicators of disease severity.
Conclusions: Nectin-4 is a potential new diagnostic and predictive biomarker for severe pre-eclampsia.